SCHEMBL5390935

SCHEMBL5390935

O=[N+]([O-])c1cccc([CH]Br)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 3/20 0.65
FBP1 P09467 2/20 0.62
VCP P55072 1/20 0.62
CYP19A1 P11511 1/20 0.62
TSHR P16473 3/20 0.61
LMNA P02545 1/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
GLO1 Q04760 1/20 0.56
ALDH1A1 P00352 4/20 0.53
MAPT P10636 2/20 0.53
METAP1 P53582 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
ACHE P22303 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ALOX15 P16050 1/20 0.52
AMY1A P0DUB6 1/20 0.51
HTT P42858 1/20 0.51
MAOB P27338 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9422259 0.85 NFE2L2 (0.77) NFE2L2FBP1VCPCYP19A1TSHR
SCHEMBL18640461 0.85 NFE2L2 (0.77) NFE2L2FBP1VCPCYP19A1TSHR
SCHEMBL29420866 0.85 NFE2L2 (0.77) NFE2L2FBP1VCPCYP19A1TSHR
SCHEMBL28019580 0.84 NFE2L2 (0.65) NFE2L2FBP1VCPCYP19A1TSHR
SCHEMBL15498134 0.83 NFE2L2 (0.89) NFE2L2FBP1VCPCYP19A1TSHR
SCHEMBL14880346 0.83 NFE2L2 (0.69) NFE2L2FBP1VCPCYP19A1TSHR
3-Nitrobenzaldehyde SCHEMBL29573715 0.82 NFE2L2 (0.67) NFE2L2FBP1VCPCYP19A1TSHR
3-Nitrobenzaldehyde SCHEMBL54487 0.82 NFE2L2 (0.67) NFE2L2FBP1VCPCYP19A1TSHR
SCHEMBL123416 0.80 NFE2L2 (0.65) NFE2L2FBP1VCPCYP19A1TSHR
SCHEMBL9727291 0.80 NFE2L2 (0.65) NFE2L2FBP1VCPCYP19A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114181207-B Beta-carboline compounds, preparation method thereof and application thereof in resisting Alzheimer disease 中国人民解放军北部战区总医院 2022-12-13 CN claimed
CN-105541801-A Method for synthesizing EZH2 methyltransferase inhibitor GSK126 UNIV CHANGZHOU 2016-05-04 CN claimed
CN-110325523-A Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2019-10-11 CN disclosed
WO-2019154366-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏奥赛康药业有限公司 2019-08-15 WO disclosed
CN-105294670-B Organic electroluminescent compounds and its organic photoelectric device 上海天马有机发光显示技术有限公司 2019-07-09 CN disclosed
CN-106795154-B Isoquinolinone derivatives for treating cancer 皮埃尔法布雷医药公司 2019-07-05 CN disclosed
CN-109562111-A CK2 inhibitor, its composition and method 北极星药业股份有限公司 2019-04-02 CN disclosed
CN-105324379-B Benzimidazole derivatives as bromodomain inhibitors 吉利德科学公司 2018-12-04 CN disclosed
CN-108929263-A Aryl amide Kv2.1 inhibitor and preparation method thereof, pharmaceutical composition and purposes 中国医学科学院药物研究所 2018-12-04 CN disclosed
CN-107922375-A Target the antitumoral compounds and its application method of IDH2 mutation 正大天晴药业集团股份有限公司 2018-04-17 CN disclosed
CN-105541801-A Method for synthesizing EZH2 methyltransferase inhibitor GSK126 UNIV CHANGZHOU 2016-05-04 CN disclosed
CN-103857681-A Novel macrocycles as factor XIA inhibitors BRISTOL MYERS SQUIBB CO 2014-06-11 CN disclosed
CN-102229562-B Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity SANTEN PHARMACEUTICAL CO LTD 2013-11-13 CN disclosed
CN-103209960-A Sulfonamide compounds useful as CYP17 inhibitors BRISTOL MYERS SQUIBB CO 2013-07-17 CN disclosed
CN-103002735-A Modulators of 5-ht receptors and methods of use thereof ABBVI CO 2013-03-27 CN disclosed
US-7285664-B2 Heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments S.C.R.A.S. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2007-10-23 US disclosed
US-20050227991-A1 New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments IPSEN PHARMA S.A.S. (FR) 2005-10-13 US disclosed
US-6936715-B2 Lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2005-08-30 US disclosed
US-20030105107-A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines IPSEN PHARMA S.A.S. (FR) 2003-06-05 US disclosed
WO-2002020630-A1 PROCESS FOR THE PREPARATION OF GLYCEROL-BASED CROSSLINKED POLYMERIC GELS LIPAL BIOCHEMICALS (CH) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105107-A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines LTC4S, LPO, COASY NFE2L2 191/4885FBP1 924/4885VCP 2409/4885
US-20050227991-A1 New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments LPO, LTC4S, BBOX1 NFE2L2 184/4885FBP1 970/4885VCP 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.